Long-term treatment of antiphospholipid syndrome-associated cerebral arterial thromboses with intravenous immunoglobulin: a case report

被引:0
|
作者
B. Arabshahi
E. D. Thompson
E. M. Smergel
D. P. Goldsmith
机构
[1] St. Christopher’s Hospital for Children/Drexel University College of Medicine,Section of Rheumatology
[2] St. Christopher’s Hospital for Children/Drexel University College of Medicine,Department of Radiology
[3] The Center for Childhood Arthritis and Rheumatic Diseases,undefined
来源
Clinical Rheumatology | 2007年 / 26卷
关键词
Antiphospholipid antibody syndrome; Child; IVIG; Stroke;
D O I
暂无
中图分类号
学科分类号
摘要
We report a now 13-year-old male with trisomy 21, hypothyroidism, and insulin-dependent diabetes who developed acute hemiplegia due to the antiphospholipid antibody syndrome (APS) at age four. The risks of long-term anticoagulation were initially considered to be high; hence, he was treated with monthly infusions of intravenous immunoglobulin (IVIG) at 2 g/kg for 2 years and then every other month for 7 years. Antiphospholipid antibodies were no longer detectable within 6 months and have continued to be negative. There was no clinical deterioration or further changes on magnetic resonance arteriography over 7 years. IVIG may be an alternative therapeutic choice for children with APS who are not candidates for conventional anticoagulation.
引用
收藏
页码:251 / 253
页数:2
相关论文
共 13 条
  • [1] Long-term treatment of antiphospholipid syndrome-associated cerebral arterial thromboses with intravenous immunoglobulin: a case report
    Arabshahi, B.
    Thompson, E. D.
    Smergel, E. M.
    Goldsmith, D. P.
    CLINICAL RHEUMATOLOGY, 2007, 26 (02) : 251 - 253
  • [2] Intravenous immunoglobulin in antiphospholipid syndrome and maternal floor infarction when standard treatment fails: A case report
    Chang, P
    Millar, D
    Tsang, P
    Lim, K
    Houlihan, E
    Stephenson, M
    AMERICAN JOURNAL OF PERINATOLOGY, 2006, 23 (02) : 125 - 129
  • [3] CASE REPORT A multidisciplinary approach to the treatment of oral manifestations associated with Beckwith-Wiedemann syndrome A long-term case report
    Teresa Abeleira, Maria
    Manuel Seoane-Romero, Juan
    Outumuro, Mercedes
    Caamano, Flor
    Suarez, David
    Tomas Carmona, Inmaculada
    JOURNAL OF THE AMERICAN DENTAL ASSOCIATION, 2011, 142 (12) : 1357 - 1364
  • [4] Cerebral infarction 3 weeks after intravenous immunoglobulin for Miller Fisher syndrome: A case report
    Chang T.
    De Alwis J.S.
    Samarasekara N.
    Rajapakse S.
    Journal of Medical Case Reports, 8 (1)
  • [5] Long-term treatment of Lewis-Sumner syndrome with subcutaneous immunoglobulin infusions
    Bayas, Antonios
    Gold, Ralf
    Naumann, Markus
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2013, 324 (1-2) : 53 - 56
  • [6] A case of successful pregnancy following multidrug treatment including rituximab and intravenous immunoglobulin for primary antiphospholipid antibody syndrome refractory to conventional treatment
    Nagata, Mayu
    Kaneko, Kayoko
    Kohno, Chie
    Mishima, Shuko
    Okazaki, Yuka
    Murashima, Atsuko
    MODERN RHEUMATOLOGY CASE REPORTS, 2020, 4 (01) : 47 - 50
  • [7] Long-term outcomes of plasma exchange versus intravenous immunoglobulin for the treatment of Guillain-Barre Syndrome: A double-blind, randomized clinical trial
    Haridy, Nourelhoda A.
    Shehab, Mohamed M.
    Khedr, Eman M.
    RESTORATIVE NEUROLOGY AND NEUROSCIENCE, 2023, 41 (5-6) : 203 - 217
  • [8] Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen:: a case with long-term follow-up
    Ruckert, A.
    Glimm, H.
    Lubbert, M.
    Gruellich, C.
    LUPUS, 2008, 17 (08) : 757 - 760
  • [9] Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy
    Klehmet, Juliane
    Tackenberg, Bjorn
    Haas, Judith
    Kieseier, Bernd C. C.
    BMC NEUROLOGY, 2023, 23 (01)
  • [10] Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy
    Juliane Klehmet
    Björn Tackenberg
    Judith Haas
    Bernd C. Kieseier
    BMC Neurology, 23